SciELO - Scientific Electronic Library Online

vol.90 número4Compromiso cardiovascular en pacientes recuperados de COVID-19: ¿realidad o fantasía?Tejido adiposo epicárdico como predictor de enfermedad coronaria. ¿Un nuevo parámetro para la estratificación del riesgo cardiovascular? índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados




  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO


Revista argentina de cardiología

versión On-line ISSN 1850-3748


SIGAL, ALAN R. et al. Present Use of Aspirin as an Antithrombotic Agent: Current or Outdated Drug?. Rev. argent. cardiol. [online]. 2022, vol.90, n.4, pp.294-303.  Epub 01-Ago-2022. ISSN 1850-3748.

Acetylsalicylic acid, or aspirin, is one of pharmacological tools most widely used in the care of cardiovascular patients. For years, it has been widely used in primary and secondary prevention to reduce cardiovascular risk.

Aspirin utilization has been questioned in recent times, with new trials in different scenarios of cardiovascular disease, such as peripheral vascular disease, stroke, primary prevention in the context of modern medical treatment, or in patients with acute coronary syndrome and concomitant need for anticoagulation. In turn, new studies question the need to maintain aspirin for 12 months together with a thienopyridine after an acute coronary syndrome, suggesting shorter regimens.

In this review, we evaluate the evidence behind the current indications for aspirin use in different clinical scenarios and provide recommendations on a case-by-case basis.

Palabras clave : Aspirin; Prevention; Evidence.

        · resumen en Español     · texto en Español     · Español ( pdf )